199 related articles for article (PubMed ID: 29799521)
1. Heat shock factor 1 confers resistance to lapatinib in ERBB2-positive breast cancer cells.
Yallowitz A; Ghaleb A; Garcia L; Alexandrova EM; Marchenko N
Cell Death Dis; 2018 May; 9(6):621. PubMed ID: 29799521
[TBL] [Abstract][Full Text] [Related]
2. HER2/ErbB2 activates HSF1 and thereby controls HSP90 clients including MIF in HER2-overexpressing breast cancer.
Schulz R; Streller F; Scheel AH; Rüschoff J; Reinert MC; Dobbelstein M; Marchenko ND; Moll UM
Cell Death Dis; 2014 Jan; 5(1):e980. PubMed ID: 24384723
[TBL] [Abstract][Full Text] [Related]
3. Ganetespib targets multiple levels of the receptor tyrosine kinase signaling cascade and preferentially inhibits ErbB2-overexpressing breast cancer cells.
Lee H; Saini N; Howard EW; Parris AB; Ma Z; Zhao Q; Zhao M; Liu B; Edgerton SM; Thor AD; Yang X
Sci Rep; 2018 May; 8(1):6829. PubMed ID: 29717218
[TBL] [Abstract][Full Text] [Related]
4. ErbB2 inhibition by lapatinib promotes degradation of mutant p53 protein in cancer cells.
Li D; Marchenko ND
Oncotarget; 2017 Jan; 8(4):5823-5833. PubMed ID: 27791982
[TBL] [Abstract][Full Text] [Related]
5. Receptor tyrosine kinase ERBB4 mediates acquired resistance to ERBB2 inhibitors in breast cancer cells.
Canfield K; Li J; Wilkins OM; Morrison MM; Ung M; Wells W; Williams CR; Liby KT; Vullhorst D; Buonanno A; Hu H; Schiff R; Cook RS; Kurokawa M
Cell Cycle; 2015; 14(4):648-55. PubMed ID: 25590338
[TBL] [Abstract][Full Text] [Related]
6. HSP90 inhibitor, AUY922, debilitates intrinsic and acquired lapatinib-resistant HER2-positive gastric cancer cells.
Park KS; Hong YS; Choi J; Yoon S; Kang J; Kim D; Lee KP; Im HS; Lee CH; Seo S; Kim SW; Lee DH; Park SR
BMB Rep; 2018 Dec; 51(12):660-665. PubMed ID: 30591093
[TBL] [Abstract][Full Text] [Related]
7. Intrinsic proteotoxic stress levels vary and act as a predictive marker for sensitivity of cancer cells to Hsp90 inhibition.
Pastorek M; Muller P; Coates PJ; Vojtesek B
PLoS One; 2018; 13(8):e0202758. PubMed ID: 30138434
[TBL] [Abstract][Full Text] [Related]
8. Cholesterol content in cell membrane maintains surface levels of ErbB2 and confers a therapeutic vulnerability in ErbB2-positive breast cancer.
Zhang J; Li Q; Wu Y; Wang D; Xu L; Zhang Y; Wang S; Wang T; Liu F; Zaky MY; Hou S; Liu S; Zou K; Lei H; Zou L; Zhang Y; Liu H
Cell Commun Signal; 2019 Feb; 17(1):15. PubMed ID: 30786890
[TBL] [Abstract][Full Text] [Related]
9. Hypoxia/HIF1α induces lapatinib resistance in ERBB2-positive breast cancer cells via regulation of DUSP2.
Karakashev SV; Reginato MJ
Oncotarget; 2015 Feb; 6(4):1967-80. PubMed ID: 25596742
[TBL] [Abstract][Full Text] [Related]
10. Novel Hsp90 inhibitor FW-04-806 displays potent antitumor effects in HER2-positive breast cancer cells as a single agent or in combination with lapatinib.
Huang W; Wu QD; Zhang M; Kong YL; Cao PR; Zheng W; Xu JH; Ye M
Cancer Lett; 2015 Jan; 356(2 Pt B):862-71. PubMed ID: 25449780
[TBL] [Abstract][Full Text] [Related]
11. PI3K independent activation of mTORC1 as a target in lapatinib-resistant ERBB2+ breast cancer cells.
Jegg AM; Ward TM; Iorns E; Hoe N; Zhou J; Liu X; Singh S; Landgraf R; Pegram MD
Breast Cancer Res Treat; 2012 Dec; 136(3):683-92. PubMed ID: 23089982
[TBL] [Abstract][Full Text] [Related]
12. A model of acquired autoresistance to a potent ErbB2 tyrosine kinase inhibitor and a therapeutic strategy to prevent its onset in breast cancer.
Xia W; Bacus S; Hegde P; Husain I; Strum J; Liu L; Paulazzo G; Lyass L; Trusk P; Hill J; Harris J; Spector NL
Proc Natl Acad Sci U S A; 2006 May; 103(20):7795-800. PubMed ID: 16682622
[TBL] [Abstract][Full Text] [Related]
13. A gain-of-function mutant p53-HSF1 feed forward circuit governs adaptation of cancer cells to proteotoxic stress.
Li D; Yallowitz A; Ozog L; Marchenko N
Cell Death Dis; 2014 Apr; 5(4):e1194. PubMed ID: 24763051
[TBL] [Abstract][Full Text] [Related]
14. An insertion mutation of ERBB2 enhances breast cancer cell growth and confers resistance to lapatinib through AKT signaling pathway.
Yang ZY; Yang L; Xu CW; Wang XJ; Lei L
Biol Open; 2020 Jan; 9(1):. PubMed ID: 31980423
[TBL] [Abstract][Full Text] [Related]
15. Resistance to ErbB2 tyrosine kinase inhibitors in breast cancer is mediated by calcium-dependent activation of RelA.
Xia W; Bacus S; Husain I; Liu L; Zhao S; Liu Z; Moseley MA; Thompson JW; Chen FL; Koch KM; Spector NL
Mol Cancer Ther; 2010 Feb; 9(2):292-9. PubMed ID: 20124457
[TBL] [Abstract][Full Text] [Related]
16. ERRF sensitizes ERBB2-positive breast cancer cells to lapatinib treatment likely by attenuating MCL1 and ERBB2 expression.
Qi L; Zhang B; Zhang S; Ci X; Wu Q; Ma G; Luo A; Fu L; King JL; Nahta R; Dong JT
Oncotarget; 2017 May; 8(22):36054-36066. PubMed ID: 28415602
[TBL] [Abstract][Full Text] [Related]
17. The deubiquitylase USP2 maintains ErbB2 abundance via counteracting endocytic degradation and represents a therapeutic target in ErbB2-positive breast cancer.
Zhang J; Liu S; Li Q; Shi Y; Wu Y; Liu F; Wang S; Zaky MY; Yousuf W; Sun Q; Guo D; Wang T; Zhang Y; Wang Y; Li M; Liu H
Cell Death Differ; 2020 Sep; 27(9):2710-2725. PubMed ID: 32327714
[TBL] [Abstract][Full Text] [Related]
18. Inhibition of Lapatinib-Induced Kinome Reprogramming in ERBB2-Positive Breast Cancer by Targeting BET Family Bromodomains.
Stuhlmiller TJ; Miller SM; Zawistowski JS; Nakamura K; Beltran AS; Duncan JS; Angus SP; Collins KA; Granger DA; Reuther RA; Graves LM; Gomez SM; Kuan PF; Parker JS; Chen X; Sciaky N; Carey LA; Earp HS; Jin J; Johnson GL
Cell Rep; 2015 Apr; 11(3):390-404. PubMed ID: 25865888
[TBL] [Abstract][Full Text] [Related]
19. Proteasome Inhibitors Suppress ErbB Family Expression through HSP90-Mediated Lysosomal Degradation.
Huynh TK; Ho CY; Tsai CH; Wang CK; Chen YJ; Bau DT; Tu CY; Li TS; Huang WC
Int J Mol Sci; 2019 Sep; 20(19):. PubMed ID: 31569723
[TBL] [Abstract][Full Text] [Related]
20. Acquired resistance to small molecule ErbB2 tyrosine kinase inhibitors.
Chen FL; Xia W; Spector NL
Clin Cancer Res; 2008 Nov; 14(21):6730-4. PubMed ID: 18980964
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]